Shanghai MicroPort MedBot Group Co Ltd
HKEX:2252
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
S
|
Shanghai MicroPort MedBot Group Co Ltd
HKEX:2252
|
25.8B HKD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
189.2B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
172B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
137.5B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
135.6B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
133.3B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
58.7B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.1B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.8B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
36.7B USD |
Loading...
|
Market Distribution
| Min | -409 046.1% |
| 30th Percentile | -1.4% |
| Median | 4.2% |
| 70th Percentile | 10.3% |
| Max | 876.4% |
Other Profitability Ratios
Shanghai MicroPort MedBot Group Co Ltd
Glance View
Shanghai MicroPort MedBot Group Co Ltd is a dynamic player in the medical innovation sector, strategically positioned at the crossroads of advanced technology and healthcare. Born out of a vision to revolutionize surgical practices, MedBot has dedicated itself to the development and commercialization of robotic-assisted systems. The company leverages cutting-edge research and development to create robotic platforms that aid surgeons in performing complex procedures with enhanced precision and control. Operating in a field where precision is paramount, MedBot's products are designed to minimize complications and reduce recovery times, catering to a global demand for improved surgical outcomes. MedBot generates its revenue by selling these sophisticated surgical robots to hospitals and healthcare institutions worldwide. Beyond the initial sale, the company benefits from offering ongoing service contracts, training, and support to ensure seamless integration and optimal performance of their products. Additionally, it capitalizes on the sale of consumables and replacement parts required for the long-term operation of their systems. Through its commitment to innovation and focus on addressing the complexities of surgical procedures, Shanghai MicroPort MedBot Group has carved out a distinctive niche, continually expanding its influence within the expanding scope of minimally invasive surgery.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Shanghai MicroPort MedBot Group Co Ltd is -104.2%, which is above its 3-year median of -640.9%.
Over the last 3 years, Shanghai MicroPort MedBot Group Co Ltd’s Operating Margin has increased from -25 264% to -104.2%. During this period, it reached a low of -25 264% on Jun 30, 2022 and a high of -104.2% on Jun 30, 2025.